TVARDI THERAPEUTICS, INC.: diluted weighted-average shares
Diluted weighted-average shares for TVARDI THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All TVARDI THERAPEUTICS, INC. financial histories
What this measure means
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 7,783,182 | shares | 2026-03-31 | 10-K · 0001104659-26-037729 |
| 2024-01-01 | 2024-12-31 | 2,574,233 | shares | 2026-03-31 | 10-K · 0001104659-26-037729 |
| 2023-01-01 | 2023-12-31 | 4,512,422 | shares | 2025-03-11 | 10-K · 0001558370-25-002705 |
| 2022-01-01 | 2022-12-31 | 4,471,130 | shares | 2025-03-11 | 10-K · 0001558370-25-002705 |
| 2021-01-01 | 2021-12-31 | 50,718,765 | shares | 2024-03-06 | 10-K · 0001558370-24-002609 |
| 2020-01-01 | 2020-12-31 | 47,915,030 | shares | 2023-03-06 | 10-K · 0001558370-23-002913 |
| 2019-01-01 | 2019-12-31 | 42,669,333 | shares | 2022-03-01 | 10-K · 0001558370-22-002555 |
| 2018-01-01 | 2018-12-31 | 35,892,786 | shares | 2021-02-25 | 10-K · 0001558370-21-001839 |
| 2017-01-01 | 2017-12-31 | 31,202,842 | shares | 2020-02-27 | 10-K · 0001558370-20-001659 |
| 2016-01-01 | 2016-12-31 | 27,279,008 | shares | 2019-03-12 | 10-K · 0001564590-19-007389 |
| 2015-01-01 | 2015-12-31 | 24,620,372 | shares | 2018-03-15 | 10-K · 0001564590-18-005879 |
| 2014-01-01 | 2014-12-31 | 20,965,935 | shares | 2017-03-10 | 10-K · 0001193125-17-077107 |
| 2013-01-01 | 2013-12-31 | 4,133,138 | shares | 2016-03-11 | 10-K · 0001193125-16-500345 |
| 2012-01-01 | 2012-12-31 | 3,299,993 | shares | 2015-03-27 | 10-K · 0001193125-15-107249 |
Related financial histories
- TVARDI THERAPEUTICS, INC.: total assets
- TVARDI THERAPEUTICS, INC.: total liabilities
- TVARDI THERAPEUTICS, INC.: stockholders equity
- TVARDI THERAPEUTICS, INC.: cash and cash equivalents
- TVARDI THERAPEUTICS, INC.: net income or loss
- TVARDI THERAPEUTICS, INC.: operating cash flow
- TVARDI THERAPEUTICS, INC.: capital expenditure payments
- TVARDI THERAPEUTICS, INC.: revenue
- TVARDI THERAPEUTICS, INC.: contract revenue excluding tax
- TVARDI THERAPEUTICS, INC.: financing cash flow
- TVARDI THERAPEUTICS, INC.: investing cash flow
- TVARDI THERAPEUTICS, INC.: retained earnings or deficit
- TVARDI THERAPEUTICS, INC.: basic weighted-average shares
- TVARDI THERAPEUTICS, INC.: basic earnings per share
- TVARDI THERAPEUTICS, INC.: diluted earnings per share
- TVARDI THERAPEUTICS, INC.: income tax expense or benefit
- TVARDI THERAPEUTICS, INC.: net property, plant and equipment
- TVARDI THERAPEUTICS, INC.: share-based compensation expense
- TVARDI THERAPEUTICS, INC.: operating income or loss
- TVARDI THERAPEUTICS, INC.: current assets
- TVARDI THERAPEUTICS, INC.: current liabilities
- TVARDI THERAPEUTICS, INC.: current accounts payable
- TVARDI THERAPEUTICS, INC.: net current accounts receivable
- TVARDI THERAPEUTICS, INC.: operating expenses
- TVARDI THERAPEUTICS, INC.: net inventory
- TVARDI THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- TVARDI THERAPEUTICS, INC. / CIK 0001346830
- Captured
- 2026-09-20T07:54:49.691Z
- SEC response SHA-256
77eb2a9ae7f2617236c5c8a2a3bc505a517b6fee7b42085d14193ea9e819a05c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001346830.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))